Ratio Therapeutics, Inc.

Novartis is paying $50 million upfront to license a peptide-based radiopharmaceutical asset from China-headquartered Zonsen PepLib Biotech. The Monday release did not name the candidate, its target or what stage of development it is in. What is known is that PepLib, founded in 2017, is focused on developing peptide-based therapies, including peptide-radionuclide conjugates. The biotech’s preclinical pipeline includes a “radiopharmaceutical carrier” program at the lead-optimization stage. Novartis will be responsible for developing and commercializing the licensed candidate. PepLib could get an undisclosed amount in milestones as well as tiered royalties on future sales. The deal should “complement” Novartis’ existing portfolio of radioligand therapies (RLTs), according to the release. The Swiss drugmaker is currently a market leader in RLTs due to Pluvicto for metastatic castration-resistant prostate cancer and Lutathera for gastroenteropancreatic neuroendocrine tumors. The two assets together pulled almost $800 million in third-quarter sales last year. Error: Survey not found. In its clinical RLT pipeline, Novartis is advancing a lutetium-based candidate targeting GRPR and a separate program targeting FAP, among others. The company has been ramping up its capabilities in the space, opening its third US-based RLT manufacturing site in November. Last week, it unveiled plans to build a fourth factory in Florida. In November, Novartis signed a licensing pact with Ratio Therapeutics for its SSTR2-targeting radiopharmaceutical program. In 2024, it acquired radiopharmaceutical startup Mariana Oncology for $1 billion upfront . In a separate announcement on Monday, Novartis licensed a preclinical candidate for Alzheimer’s disease from SciNeuro for $165 million upfront. In December, it teamed up with London-based biotech Relation to discover new drugs for immune diseases with the help of AI.

AstraZeneca doubled down on radiopharmaceuticals last March with its $2 billion buyout of Fusion Pharmaceuticals. Pharma giant AstraZeneca has expanded its supply deal with Michigan-based medical radioisotope producer Niowave, establishing a 10-year deal for the delivery of Actinium-225 (Ac-225), a radioisotope that has shown promise in the development of targeted cancer therapy. AZ exercised its option to increase capacity in order to secure reliable supply of the isotope for the drugmaker’s expanding pipeline of radioconjugates, which use alpha particles to target and eliminate cancer cells, Niowave said in a Dec. 18 press release.Financial terms of the supply deal weren’t disclosed.“Our expanded agreement with AstraZeneca underscores Niowave's central role in scaling high-quality production of medical radioisotopes for the development of targeted cancer treatments,” Mike Zamiara, Niowave’s chief executive, said in a statement. “We are pleased to play a role in ensuring that AstraZeneca's promising pipeline of radioconjugates have the isotope supply they need.”Niowave, which was spun out of Michigan State University's National Superconducting Cyclotron Laboratory in 2005, boasts superconducting linear accelerator technology and radiochemistry that allow for sustainable production to address the limited supply of Ac-225.The radioisotope emits alpha particles that deliver very potent and DNA-destructive energy that can be delivered precisely to destroy tumors while limiting any damage to surrounding healthy tissue, the company explained. For its part, AZ doubled down on radiopharmaceuticals last March with its $2 billion buyout of Fusion Pharmaceuticals. AZ had initially collaborated with Fusion beginning in 2020 before moving to purchase its partner, whose lead candidate, FPI-2265, is a PSMA-directed radiotherapy in phase 2 development as a treatment for metastatic castration-resistant prostate cancer.  Radioisotopes form a key component in the cutting-edge cancer treatments known as radiopharmaceuticals. Deals to boost production of the specialized ingredient have gained momentum in recent years, and the pace has not let up in 2025. Last week, Bicycle Therapeutics secured a deal with two U.K. nuclear agencies for 400 tons of reprocessed uranium it needs to develop potential radioconjugate drugs to treat cancer.And, in August, Nusano opened the doors to 190,000-square-foot production facility in Salt Lake City that is capable of churning out more than 40 different radioisotopes used for cancer diagnostics and therapeutics.Earlier this year, meanwhile, Ratio Therapeutics unveiled plans to build a new research and manufacturing plant, also in Salt Lake City, while PharmaLogic shelled out an undisclosed sum in April to take a majority stake in Norway’s Agilera Pharma.The move by PharmaLogic fits into the company’s strategy to become a global CDMO leader focused specifically on radiopharmaceuticals.

BRONX, N.Y., Dec. 16, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, announced today that it has successfully supplied the first cohort dosing of Ratio Therapeutics' investigational FAP-targeted radiopharmaceutical, [Ac-225]-RTX-2358, for the ATLAS trial. The dose was manufactured and delivered from PharmaLogic's radiopharmaceutical manufacturing facility in the Bronx, New York, which supports clinical and commercial supply for advanced radiopharmaceutical programs. "PharmaLogic is proud of this collaboration with Ratio Therapeutics and the advancement of [Ac-225]-RTX-2358 into the clinic," said Etienne Montagut, President and CEO of PharmaLogic. "The supply of the first cohort doses from our Bronx facility underscores our commitment to supporting the development of and access to innovative radiopharmaceutical therapies around the globe." About PharmaLogic Holdings Corp. PharmaLogic is a leading global contract development and manufacturing organization (CDMO) specialized in diagnostic and therapeutic radiopharmaceuticals. With decades of industry expertise and a robust network of more than 45 facilities across the U.S., Puerto Rico, Canada, and Norway, PharmaLogic delivers comprehensive solutions spanning development, manufacturing, and distribution of both clinical and commercial-stage radiopharmaceutical products, all in accordance with the highest quality and regulatory standards. Our rapidly expanding diagnostics business leverages advanced technologies to enhance patient access to novel diagnostics in oncology, cardiology, and neurology. In the therapeutic segment, PharmaLogic is the world's only cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic to more than 30 countries across the globe. PharmaLogic is dedicated to enabling global patient access to radiopharmaceuticals through strategic development partnerships with industry innovators, advancing the future of the field and supporting our partners throughout the product lifecycle. For more information, visit radiopharmacy.com and follow us on LinkedIn. About the ATLAS Trial The ATLAS trial is a Phase 1/2 open-label clinical trial (clinicaltrials.gov identifier, NCT07156565) designed to assess the safety, tolerability, dosimetry, biodistribution, pharmacokinetics, and preliminary anti-tumor activity of [Ac-225]-RTX-2358, a highly selective, FAP targeted radiotherapeutic labeled with Actinium 225, in patients with relapsed or refractory soft tissue sarcomas that express FAP. The study consists of two phases: an ascending administered activity phase (Phase 1) and an expansion phase (Phase 2). For patients to be eligible to receive treatment, FAP expression will be assessed using a [Cu-64]-LNTH-1363S PET scan. In the Phase 1 portion, patients with FAP positive sarcomas will receive intravenous injections of [Ac-225]-RTX-2358 once every eight weeks, for up to six treatment cycles over a 12-month period. Using a standard 3+3 dose escalation design, participants will be assigned to one of three groups, each receiving an increasing dose level to determine the maximum tolerated dose and establish a recommended dose for the expansion phase. Cohort expansion will be allowed to a max of 10 patients per cohort, enabling up to 26 patients to be treated and evaluated during the Phase 1 portion of the trial. This will allow better characterization of safety and tolerability as well as the assessment of preliminary efficacy. Safety data from each group will be reviewed by an independent Safety Review Committee before dose escalation proceeds. The Phase 2 portion of the study will evaluate the efficacy and safety of [Ac-225]-RTX-2358 in up to 50 patients. [Ac-225]-RTX-2358 is being manufactured by Pharmalogic. [Cu-64]-LNTH-1363S is being provided by Lantheus and manufactured by PharmaLogic. About Ratio Therapeutics Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio's proprietary R&D platforms, Trillium™ and Macropa™, enable the development of fit-for-purpose heterobifunctional radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading. The company maintains a strong commitment to manufacturing through its collaboration with PharmaLogic and its own state-of-the-art facility located in Salt Lake City, Utah, ensuring reliable supply and quality in radiopharmaceutical production. Please visit for more information and follow us on Twitter (X) and LinkedIn. SOURCE PharmaLogic Holdings Corp 21% more press release views with Request a Demo